|
|
||||||||
1 Department of Physiology, Faculty of Medical Sciences, New University of Lisbon, Campo Mártires da Pátria 130, 1169-056 Lisbon; 2 Department of Chemistry and Biochemistry, Center for Studies in Biochemistry and Physiology, Faculty of Sciences, University of Lisbon, Campo Grande, 1749-016 Lisbon; 3 Superior School of Health Egas Moniz, Quinta da Granja, Monte da Caparica, 2829-511 Caparica; 4 Institute of Scientific Research Bento da Rocha Cabral, Calçada Bento da Rocha Cabral No. 14, 1250-047 Lisbon; and 5 Portuguese Diabetes Association, 1250-203 Lisbon, Portugal
We tested the hypothesis that
hepatic nitric oxide (NO) and glutathione (GSH) are involved in the
synthesis of a putative hormone referred to as hepatic
insulin-sensitizing substance HISS. Insulin action was assessed in
Wistar rats using the rapid insulin sensitivity test (RIST). Blockade
of hepatic NO synthesis with NG-nitro-L-arginine methyl ester
(L-NAME, 1.0 mg/kg intraportal) decreased insulin
sensitivity by 45.1 ± 2.1% compared with control (from
287.3 ± 18.1 to 155.3 ± 10.1 mg glucose/kg,
P < 0.05). Insulin sensitivity was restored to
321.7 ± 44.7 mg glucose/kg after administration of an NO donor,
intraportal SIN-1 (5 mg/kg), which promotes GSH nitrosation, but not
after intraportal sodium nitroprusside (20 nmol · kg
1 · min
1), which
does not nitrosate GSH. We depleted hepatic GSH using the GSH
synthesis inhibitor l-buthionine-[S,R]-sulfoximine (BSO, 2 mmol/kg body wt ip for 20 days), which reduced insulin sensitivity by
39.1%. Insulin sensitivity after L-NAME was not
significantly different between BSO- and sham-treated animals. SIN-1
did not reverse the insulin resistance induced by L-NAME in
the BSO-treated group. These results support our hypothesis that NO and
GSH are essential for insulin action.
hepatic nitric oxide synthase; hepatic parasympathetic nerves; type 2 diabetes
This article has been cited by other articles:
![]() |
M. C. Moore, C. A. DiCostanzo, M. S. Smith, B. Farmer, T. D. Rodewald, D. W. Neal, P. E. Williams, and A. D. Cherrington Hepatic portal venous delivery of a nitric oxide synthase inhibitor enhances net hepatic glucose uptake Am J Physiol Endocrinol Metab, April 1, 2008; 294(4): E768 - E777. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. An, C. A. DiCostanzo, M. C. Moore, D. S. Edgerton, D. P. Dardevet, D. W. Neal, and A. D. Cherrington Effects of the nitric oxide donor SIN-1 on net hepatic glucose uptake in the conscious dog Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E300 - E306. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Guarino, N. C. Correia, W. W. Lautt, and M. P. Macedo Insulin sensitivity is mediated by the activation of the ACh/NO/cGMP pathway in rat liver Am J Physiol Gastrointest Liver Physiol, September 1, 2004; 287(3): G527 - G532. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |